Lifeboat Foundation

By Julia Robinson 2024–06-24T12:55:00

Researchers are on a quest to outsmart and overcome the sophisticated security system of the brain. Julia Robinson reports on some of the approaches being studied.

A remarkable discovery in the Siberian permafrost: a 44,000-year-old wolf with preserved stomach contents and organs.

This single-center longitudinal cohort study has followed known carriers of PRNP pathogenic variants at risk for prion disease, individuals with a close relative who died of genetic prion disease but who have not undergone predictive genetic testing, and controls. All participants were asymptomatic at first visit and returned roughly annually. We determined PRNP genotypes, measured NfL and GFAP in plasma, and RT-QuIC, total PrP, NfL, T-tau, and beta-synuclein in CSF.

Cirrus Therapeutics, the University of Bristol, and London’s Global University Institute of Ophthalmology have discovered a new treatment for age-related macular degeneration (AMD), the leading cause of vision loss among older adults.

Featured on the cover of the journal Science Translational Medicine, this research reveals that boosting a specific protein, IRAK-M, in retinal cells could offer a new and highly effective therapy for AMD.

AMD can severely impact a person’s vision. Patients suffering from AMD often start with blurred vision or seeing a black dot in their central vision, which can ultimately expand to the point where there is no useful central vision. Currently, AMD affects approximately 200 million people worldwide, a number projected to rise to 288 million by 2040 with graying populations. The exact cause of AMD is complex and thought to involve a combination of aging, environmental, and lifestyle factors.

The probe also achieved stable neural recordings in rat brains for up to two years, showing excellent biocompatibility and long-term recording stability, state news agency Xinhua reported.

Cheng Heping, with the Chinese Academy of Sciences and director of the National Centre for Biomedical Imaging Science at Peking University, told Xinhua that the achievement provided a powerful tool for high-throughput simultaneous monitoring of activity in multiple brain regions, and for exploring the relationships between neural activity and behaviour.

This study uncoversthe pivotal role of the enzyme METTL4 in promoting tumor metastasis through the mediation of nuclear N6-methyldeoxyadenosine (6mA) in mammalian cells. By utilizing cellular models, the study demonstrates how hypoxia induces METTL4 to mediate 6mA modifications. This process, in turn, activates genes essential for tumor metastasis, including the involvement of specific long noncoding RNA and a novel HIF-1α co-activator, ZMIZ1. These findings not only shed light on the epigenetic mechanisms driving tumor progression but also establish METTL4 as a prognostic marker for cancer and a potential target for therapeutic intervention. The promise of this discovery lies in its potential to inspire new strategies for combating hypoxia-induced tumor progression, opening avenues for further research and development in cancer treatment.

DNA N6-methyldeoxyadenosine (6mA) has been recognized in various organisms for its role in gene regulation. However, its function in mammalian cells, particularly in the context of cancer, has remained elusive. Previous studies have shown that 6mA modifications can influence gene expression and are present in several species, indicating a potential regulatory role in tumorigenesis. This research addresses a critical gap in understanding the nuclear role of 6mA and its enzymatic mediator METTL4, in mammalian tumor cells, particularly under hypoxia (a common condition in tumor microenvironments that promotes metastasis). The study posits that METTL4-mediated 6mA deposition is a key epigenetic modification that activates metastasis-inducing genes. This finding offers a new perspective on the mechanisms of tumor progression and identifying novel targets for therapeutic intervention.

Continue reading “The Enzyme Leading the Charge Against Tumor metastasis” »

Is it possible that a cure for cancer will be available in one year’s time? A team of Israeli scientists believes so.

But deep learning has a massive drawback: The algorithms can’t justify their answers. Often called the “black box” problem, this opacity stymies their use in high-risk situations, such as in medicine. Patients want an explanation when diagnosed with a life-changing disease. For now, deep learning-based algorithms—even if they have high diagnostic accuracy—can’t provide that information.

To open the black box, a team from the University of Texas Southwestern Medical Center tapped the human mind for inspiration. In a study in Nature Computational Science, they combined principles from the study of brain networks with a more traditional AI approach that relies on explainable building blocks.

The resulting AI acts a bit like a child. It condenses different types of information into “hubs.” Each hub is then transcribed into coding guidelines for humans to read—CliffsNotes for programmers that explain the algorithm’s conclusions about patterns it found in the data in plain English. It can also generate fully executable programming code to try out.

Scientists at Duke-NUS Medical School have identified how the first domino falls after a person encounters an allergen, such as peanuts, shellfish, pollen or dustmites. Their discovery, published in the April issue of Nature Immunology, could herald the development of drugs to prevent these severe reactions.

It is well established that when mast cells, a type of immune cell, mistake a harmless substance, such as peanuts or dust mites, as a threat, they release an immediate first wave of bioactive chemicals against the perceived threat. When mast cells, which reside under the skin, around blood vessels and in the linings of the airways and the gastrointestinal tract, simultaneously release their pre-stored load of bioactive chemicals into the blood, instant and systemic shock can result, which can be lethal without quick intervention.

More than 10 per cent of the global population suffers from food allergies, according to the World Health Organisation (WHO). As allergy rates continue to climb, so does the incidence of food-triggered anaphylaxis and asthma worldwide. In Singapore, asthma affects one in five children while food allergies are already the leading cause of anaphylactic shock.